Clinical Takeaway
In this phase 3 randomized controlled trial of 820 adults, the full-spectrum cannabis extract VER-01 was evaluated against placebo over 12 weeks for chronic low back pain, with follow-up extending to approximately one year. The trial design included both an open-label extension and a withdrawal phase, providing structured evidence on sustained use and discontinuation effects. Results from this large, well-controlled study contribute meaningful clinical data on cannabis-based treatment as an alternative to conventional pharmacologic options for a condition affecting hundreds of millions of people globally.
#1 Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.
Citation: Karst Matthias et al.. Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.. Nature medicine. 2025. PMID: 41023483.
Design: 5 Journal: 4 N: 2 Recency: 2 Pop: 2 Human: 1 Risk: -2
This phase 3 trial addresses a critical clinical gap by providing rigorous evidence on cannabis efficacy for chronic low back pain, a condition affecting over 500 million people globally where current pharmacotherapies demonstrate limited effectiveness and significant adverse effect profiles. The double-blind, placebo-controlled design with 820 participants and extended follow-up enables clinicians to make evidence-based decisions regarding cannabis-based therapeutics as an alternative to opioids and other conventional analgesics for CLBP management. These findings could reshape treatment guidelines for one of the most prevalent and costly pain conditions in clinical practice.
Quality Gate Alerts:
- Preclinical only
Methodological Considerations:
- Open-label design — placebo effect not excluded
Abstract: Chronic low back pain (CLBP) affects over half a billion people worldwide. Current pharmacologic treatments offer limited efficacy and carry substantial risks, warranting the development of safe and effective alternatives. This multicenter, randomized, placebo-controlled phase 3 trial evaluated the efficacy and safety of VER-01 in CLBP. It enrolled 820 adults with CLBP (VER-01, n = 394; placebo, n = 426) and included a double-blind 12-week treatment phase (phase A), a 6-month open-label extension (phase B), followed by either a 6-month continuation (phase C) or randomized withdrawal (phase D). The primary endpoint of phase A was a change in mean numeric rating scale (NRS) pain intensity, with a change in total neuropathic pain symptom inventory (NPSI) score as a key secondary endpoint in participants with a neuropathic pain component (PainDETECT > 18). The primary endpoint for phase D was time to treatment failure. The study met its primary endpoint in phase A, with a mean pain reduction of -1.9 NRS points in the VER-01 group (mean difference (MD) versus placebo = -0.6, 95% confidence interval (CI) = -0.9 to -0.3; P < 0.001). Pain further decreased to -2.9 NRS points in phase B, with effects sustained through phase C. The study also met its key secondary endpoint of phase A, with a mean NPSI decrease of -14.4 (standard error, 3.3) points from baseline in the VER-01 arm (MD versus placebo = -7.3, 95% CI = -13.2 to -1.3; P = 0.017). Although phase D did not meet its primary endpoint (hazard ratio = 0.75, 95% CI = 0.44-1.27; P = 0.288), pain increased significantly more with placebo upon withdrawal (MD = 0.5, 95% CI = 0.0-1.0; P = 0.034). In phase A, the incidence of adverse events-mostly mild to moderate and transient-was higher with VER-01 than with placebo (83.3% versus 67.3%; P < 0.001). VER-01 was well-tolerated, with no signs of dependence or withdrawal. VER-01 shows potential as a new, safe and effective treatment for CLBP. ClinicalTrials.gov registration: NCT04
💊 This phase 3 trial of a full-spectrum cannabis extract (VER-01) for chronic low back pain adds meaningful data to an evidence gap in a population with limited safe alternatives to opioids and NSAIDs, showing promise in a reasonably sized 820-patient cohort. However, several factors warrant cautious interpretation: the study’s reliance on patient-reported outcomes without clear reporting of objective functional measures, potential bias introduced by the open-label extension phase, and the inherent challenge of blinding in cannabis trials where participants often detect treatment assignment through subtle pharmacologic cues. Additionally, we lack details on specific cannabinoid ratios and dosing standardization, which limits generalizability to other full-spectrum products clinicians might encounter in practice. The 12-week primary phase is also relatively brief for evaluating treatments in a chronic condition where long-term safety and durability matter considerably. Clinically, while this work supports further investigation of full-spectrum cannabis as a potential adjunctive option for selected CL